Octave

📍 Menlo Park, United States🗓 Founded 2014👥 84 employees💰 Last funded Jun 2025
Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.
6
Total investors
0
Early stage
2
Mid stage
3
Late stage
2014
Founded
Investor geography3 countries
United States
4
Jordan
1
Switzerland
1
Investor activity2018–2025 · investors recorded per year
201822023320251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Octave?
Octave has 6 investors on record on gritt.io, 2 mid-stage and 3 late-stage investors.
When did Octave last raise funding?
The most recent investment in Octave recorded on gritt.io was in June 2025.
When was Octave founded?
Octave was founded in 2014.
What industry is Octave in?
Octave operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Octave based?
Octave is headquartered in Menlo Park, United States.